Citations

Clear

4610 citation(s) found for "Lu, Brian".

Self-scheduling Medical Visits in a Multispecialty, Multisite Medical Practice: Complexity, Challenges, and Successes
North, Frederick , Buss, Rebecca J , Nelson, Elissa M , Thompson, Matthew C , Garrison, Gregory M. , Crum, Brian A. , Buss, Rebecca , Pecina, Jennifer , Garrison, Gregory M , Crum, Brian A , Thompson, Matthew C , Pecina, Jennifer L.

Mayo Clinic

Health Services Research and Managerial Epidemiology | May 9, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23333928241253126 | PMID 38736506 Get It

Background Self-scheduling of medical visits is becoming more common but the complexity of applying multiple requirements for self-scheduling has hampered implementation. Mayo Clinic implemented self-scheduling in 2019 and has been increasing its portfolio of self-schedulable visits since then. Our aim was to show measures quantifying the complexity associated with medical visit scheduling and to describe how opportunities and challenges of scheduling complexity apply in self-scheduling. Methods We examined scheduled visits from January 1, 2022, through August 24, 2023. For seven visit categories, we counted all unique visit types that were scheduled, for both staff-scheduled and self-scheduled. We examined counts of self-scheduled visit types to identify those with highest uptake during the study period. Results There were 9555 unique visit types associated with 20.8 M (million) completed visits. Self-scheduled visit types accounted for 4.0% (838,592/20,769,699) of the completed total visits. Of seven visit categories, self-scheduled established patient visits, testing visits, and procedure visits accounted for 93.5% (784,375/838,592) of all self-scheduled visits. Established patient visits in primary care (10 visit types) accounted for 273,007 (32.6%) of all self-scheduled visits. Testing visits (blood and urine testing, 2 visit types) accounted for 183,870 (21.9%) of all self-scheduled visits. Procedure visits for screening mammograms, bone mineral density, and immunizations (8 visit types) accounted for 147,358 (17.6%) of all self-scheduled visits. Conclusion Large numbers of unique visit types comprise a major challenge for self-scheduling. Some visit types are more suitable for self-scheduling. Guideline-based procedure visits such as screening mammograms, bone mineral density exams, and immunizations are examples of visits that have high volumes and can be standardized for self-scheduling. Established patient visits and laboratory testing visits also can be standardized for self-scheduling. Despite the successes, there remain thousands of specific visit types that may need some staff-scheduler intervention to properly schedule.
The value of microvascular breast reconstruction: Cost equivalence of TRAM and DIEP flaps implications in the era of CMS reforms
Foppiani, Jose, Kim, Erin , Escobar‐Domingo, Maria J. , Taritsa, Iulianna C., Schuster, Kirsten A. , Ho, Olivia A. , Rinker, Brian, Lee, Bernard T. , Lin, Samuel J. , Foppiani, Jose , Escobar-Domingo, Maria J , Lee, Bernard T , Alvarez, Angelica Hernandez , Lee, Daniela

Mayo Clinic

Microsurgery | May 8, 2024 | Volume: 44 | Issue: 4 | Pages: No page available

10.1002/micr.31185 | PMID 38716656 Get It

AbstractBackgroundRecent CMS billing changes have raised concerns about insurance coverage for deep inferior epigastric perforator (DIEP) flap breast reconstruction. This study compared the costs and utilization of transverse rectus abdominis myocutaneous (TRAM), DIEP, and latissimus dorsi (LD) flaps in breast reconstruction.MethodThe study utilized the National Inpatient Sample database to identify female patients who underwent DIEP, TRAM, and LD flap procedures from 2016 to 2019. Key data such as patient demographics, length of stay, complications, and costs (adjusted to 2021 USD) were analyzed, focusing on differences across the flap types.ResultsA total of 17,770 weighted patient encounters were identified, with the median age being 51. The majority underwent DIEP flaps (73.5%), followed by TRAM (14.2%) and LD (12.1%) flaps. The findings revealed that DIEP and TRAM flaps had a similar length of stay (LOS), while LD flaps typically had a shorter LOS. The total hospital charges to costs using cost‐to‐charge ratio were also comparable between DIEP and TRAM flaps, whereas LD flaps were significantly less expensive. Factors such as income quartile, primary payer of hospitalization, and geographic region significantly influenced flap choice.ConclusionThe study's results appear to contradict the prevailing notion that TRAM flaps are more cost‐effective than DIEP flaps. The total hospital charges to costs using cost‐to‐charge ratio and hospital stays associated with TRAM and DIEP flaps were found to be similar. These findings suggest that changes in the insurance landscape, which may limit the use of DIEP flaps, could undermine patient autonomy while not necessarily reducing healthcare costs. Such policy shifts could favor less costly options like the LD flap, potentially altering the landscape of microvascular breast reconstruction.
MRI Vertebral Bone Quality Correlates With Interbody Cage Subsidence After Anterior Cervical Discectomy and Fusion
Bernatz, James T. , Pumford, Andrew, Mikula, Anthony L. , Bydon, Mohamad , Freedman, Brett A. , Sebastian, Arjun S. , Bernatz, James T. , Goh, Brian Chun Kim , Pinter, Zachariah W. , Michalopoulos, Giorgos D. , Huddleston, P.M. , Nassr, Ahmad , Freedman, Brett A.

Mayo Clinic

Clinical Spine Surgery | May 6, 2024 | Volume: 37 | Issue: 4 | Pages: 149-154

10.1097/bsd.0000000000001623 | PMID 38706112 Get It

Study Design: Retrospective observational study of consecutive patients Objective: The purpose of the study was to evaluate VBQ as a predictor of interbody subsidence and to determine threshold values that portend increased risk of subsidence. Summary of Background Data: Many risk factors have been reported for the subsidence of interbody cages in anterior cervical discectomy and fusion (ACDF). MRI Vertebral Bone Quality (VQB) is a relatively new radiographic parameter that can be easily obtained from preoperative MRI and has been shown to correlate with measurements of bone density such as DXA and CT Hounsfield Units. Methods: All patients who underwent 1- to 3-level ACDF using titanium interbodies with anterior plating between the years 2018 and 2020 at our tertiary referral center were included. Subsidence measurements were performed by 2 independent reviewers on CT scans obtained 6 months postoperatively. VBQ was measured on pre-operative sagittal T1 MRI by 2 independent reviewers, and values were averaged. Results: Eight-five fusion levels in 44 patients were included in the study. There were 32 levels (38%) with moderate subsidence and 12 levels with severe subsidence (14%). The average VBQ score in those patients with severe subsidence was significantly higher than those without subsidence (3.80 vs. 2.40, P<0.01). A threshold value of 3.2 was determined to be optimal for predicting subsidence (AUC=0.99) and had a sensitivity of 100% and a specificity of 94.1% in predicting subsidence. Conclusions: VBQ strongly correlates with the subsidence of interbody grafts after ACDF. A threshold VBQ score value of 3.2 has excellent sensitivity and specificity for predicting subsidence. Spine surgeons can use VBQ as a readily available screening tool to identify patients at higher risk for subsidence. Level of Evidence: Level—IV
Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease
Llibre‐Guerra, Jorge J. , Gordon, Brian A. , Hassenstab, Jason , Kramer, Joel H. , Morris, John C. , Mundada, Nidhi S. , Perrin, Richard J. , Rosen, Howard J. , Soleimani‐Meigooni, David N. , Strom, Amelia , Tsoy, Elena , Xiong, Chengjie , Chrem, Patricio, Vázquez, Silvia , Berman, Sarah , Chhatwal, Jasmeer P. , Masters, Colin L. , Farlow, Martin R. , Xiong, Chengjie , Salloway, Stephen , Day, Gregory S. , Gorno‐Tempini, Maria Luisa , Boxer, Adam L. , Joie, Renaud La , Rabinovici, Gil D. , Llibre-Guerra, Jorge J , Gordon, Brian A , Miller, Zachary , Morris, John C , Soleimani-Meigooni, David , Chhatwal, Jasmeer , Masters, Colin L , Xiong, Chengjie , La Joie, Renaud , Bateman, Randall J , Rabinovici, Gil D , Day, Gregory S , Hassenstab, Jason , Berman, Sarah , Iaccarino, Leonardo , McDade, Eric , Edwards, Lauren , Benzinger, Tammie L.S. , Li, Yan , Miller, Bruce L. , Miller, Zachary , Wang, Guoqiao , Allegri, Ricardo , Jucker, Mathias , Fox, Nick C. , Bateman, Randall J.

Mayo Clinic

Brain Communications | May 3, 2024 | Volume: 6 | Issue: 3 | Pages: No page available

10.1093/braincomms/fcae159 | PMID 38784820 Get It

Abstract Approximately 5% of Alzheimer’s disease patients develop symptoms before age 65 (early-onset Alzheimer’s disease), with either sporadic (sporadic early-onset Alzheimer’s disease) or dominantly inherited (dominantly inherited Alzheimer’s disease) presentations. Both sporadic early-onset Alzheimer’s disease and dominantly inherited Alzheimer’s disease are characterized by brain amyloid-β accumulation, tau tangles, hypometabolism and neurodegeneration, but differences in topography and magnitude of these pathological changes are not fully elucidated. In this study, we directly compared patterns of amyloid-β plaque deposition and glucose hypometabolism in sporadic early-onset Alzheimer’s disease and dominantly inherited Alzheimer’s disease individuals. Our analysis included 134 symptomatic sporadic early-onset Alzheimer’s disease amyloid-Positron Emission Tomography (PET)-positive cases from the University of California, San Francisco, Alzheimer’s Disease Research Center (mean ± SD age 59.7 ± 5.6 years), 89 symptomatic dominantly inherited Alzheimer’s disease cases (age 45.8 ± 9.3 years) and 102 cognitively unimpaired non-mutation carriers from the Dominantly Inherited Alzheimer Network study (age 44.9 ± 9.2). Each group underwent clinical and cognitive examinations, 11C-labelled Pittsburgh Compound B-PET and structural MRI. 18F-Fluorodeoxyglucose-PET was also available for most participants. Positron Emission Tomography scans from both studies were uniformly processed to obtain a standardized uptake value ratio (PIB50–70 cerebellar grey reference and FDG30–60 pons reference) images. Statistical analyses included pairwise global and voxelwise group comparisons and group-independent component analyses. Analyses were performed also adjusting for covariates including age, sex, Mini-Mental State Examination, apolipoprotein ε4 status and average composite cortical of standardized uptake value ratio. Compared with dominantly inherited Alzheimer’s disease, sporadic early-onset Alzheimer’s disease participants were older at age of onset (mean ± SD, 54.8 ± 8.2 versus 41.9 ± 8.2, Cohen’s d = 1.91), with more years of education (16.4 ± 2.8 versus 13.5 ± 3.2, d = 1) and more likely to be apolipoprotein ε4 carriers (54.6% ε4 versus 28.1%, Cramer’s V = 0.26), but similar Mini-Mental State Examination (20.6 ± 6.1 versus 21.2 ± 7.4, d = 0.08). Sporadic early-onset Alzheimer’s disease had higher global cortical Pittsburgh Compound B-PET binding (mean ± SD standardized uptake value ratio, 1.92 ± 0.29 versus 1.58 ± 0.44, d = 0.96) and greater global cortical 18F-fluorodeoxyglucose-PET hypometabolism (mean ± SD standardized uptake value ratio, 1.32 ± 0.1 versus 1.39 ± 0.19, d = 0.48) compared with dominantly inherited Alzheimer’s disease. Fully adjusted comparisons demonstrated relatively higher Pittsburgh Compound B-PET standardized uptake value ratio in the medial occipital, thalami, basal ganglia and medial/dorsal frontal regions in dominantly inherited Alzheimer’s disease versus sporadic early-onset Alzheimer’s disease. Sporadic early-onset Alzheimer’s disease showed relatively greater 18F-fluorodeoxyglucose-PET hypometabolism in Alzheimer’s disease signature temporoparietal regions and caudate nuclei, whereas dominantly inherited Alzheimer’s disease showed relatively greater hypometabolism in frontal white matter and pericentral regions. Independent component analyses largely replicated these findings by highlighting common and unique Pittsburgh Compound B-PET and 18F-fluorodeoxyglucose-PET binding patterns. In summary, our findings suggest both common and distinct patterns of amyloid and glucose hypometabolism in sporadic and dominantly inherited early-onset Alzheimer’s disease.
Self-scheduling in a Large Multispecialty and Multisite Clinic: A Retrospective, Longitudinal Examination of Multiple Self-Scheduled Visit Types
North, Frederick , Buss, Rebecca J , Nelson, Elissa M , Thompson, Matthew C , Garrison, Gregory M. , Crum, Brian A. , Buss, Rebecca , Pecina, Jennifer , Garrison, Gregory M , Crum, Brian A , Thompson, Matthew C , Pecina, Jennifer L.

Mayo Clinic

Health Services Research and Managerial Epidemiology | May 2, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23333928241249521 | PMID 38698881 Get It

Background Self-scheduling of medical visits is becoming available at many medical institutions. We aimed to examine the self-scheduled visit counts and rate of growth of self-scheduled visits in a multispecialty practice. Methods For 85 weeks extending from January 1, 2022 through August 24, 2023, we examined self-scheduled visit counts for over 1500 self-scheduled visit types. We compared completed self-scheduled visit counts to all scheduled completed visit counts for the same visit types. We collected counts of the most frequently self-scheduled visit types for each week and examined the change over time. We also determined the proportion that each visit type was self-scheduled. Results There were 20,769 699 completed visits during the course of the study that met the criteria for inclusion. Self-scheduled visits accounted for 4.0% of all completed visits (838 592/20,769 699). Over the 85-week span, self-scheduled visits rose from 3.0% to 5.3% of the total. There were 1887 unique visit types that were associated with completed visits. There were just 6 appointment visit types of the total 1887 self-scheduled visit types that accounted for 50.7% of the total 838 592 self-scheduled visits. Those 6 visit types were a lab blood test visit (19.5%, 163 K visits), two Family Medicine office visit types (13.0%, 109 K visits), a screening mammogram visit type (6.6%, 55 K visits), a scheduled express care visit type (6%, 50 K visits) and a COVID immunization visit type (5.7%, 48 K visits). Twenty-one visit types that were self-scheduled accounted for 75% of the total self-scheduled visits. Four seasonal visits, accounting for 10.6% of the total self-scheduled visits, were responsible for almost all the non-linear change in self-scheduling. Conclusion Self-scheduling accounted for a small but growing percent of all outpatient scheduled visits in a multispecialty, multisite practice. A wide range of visit types can be successfully self-scheduled.
Abstract PO1-01-01: ECOG-ACRIN EA1211: Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial)
Jacene, Heather A. , Gatsonis, Constantine, Connolly, Roisín M. , Burnette, Brian L., Stringer-Reasor, Erica , Hennessy, Maeve, Taurone, Alexander, O’Sullivan, Ciara C. , Le‐Petross, Huong T. , Sepulveda, Karla A., Mankoff, David A. , Mankoff, David A , Romanoff, Justin , Lawhn-Heath, Courtney A. , Stearns, Vered , Fowler, Amy M. , Tang, Shou-Ching , DeMichele, Angela , Wolff, Antonio C.

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO1-01-01-PO1-01-01

10.1158/1538-7445.sabcs23-po1-01-01 Get It

Abstract Background: Strategies to optimize treatment decision-making in early stage HER2-positive breast cancer are a current priority for the oncology and patient advocacy community. Recent studies suggest that early metabolic changes on FDG-PET/CT (imaging biomarker) predict response to HER2-directed therapy. The TBCRC026 trial showed that participants not obtaining a 40% reduction in SULmax by cycle 1 day 15 (C1D15) following neoadjuvant trastuzumab/pertuzumab (HP) were unlikely to obtain pCR [negative predictive value (NPV) 91%]. The ECOG-ACRIN EA1211/DIRECT trial aims to validate FDG-PET/CT as a neoadjuvant interim (niFDG-PET/CT) imaging integral biomarker in patients treated with standard HER2-directed regimens (NCT05710328). Design: EA1211/DIRECT is a multicenter, single-arm, primary imaging phase 2 study enrolling patients with stage II/III HER2-positive breast cancer. Patients undergo standard skull base-thigh FDG-PET/CT at baseline and C1D15 and receive standard of care pertuzumab-based neoadjuvant therapy followed by surgery. Eligibility: Age ≥18 years, ECOG performance status 0-2, stage IIa-IIIc, untreated HER2-positive breast cancer with known hormone receptor status, suitable to undergo FDG-PET/CT imaging and neoadjuvant therapy. Methods: ΔSULmaxD15 will be computed as: (D15 SULmax – baseline SULmax)/baseline SULmax. The primary objective is to estimate the NPV of niFDG-PET/CT for pCR using ΔSULmaxD15 of the primary breast cancer at a threshold of 40%, in patients treated with neoadjuvant HER2-directed therapy. NPV is defined as the probability that pCR will not be achieved by participants with ΔSULmaxD15 &lt; 40%. Secondary endpoints include evaluating the sensitivity, specificity, and positive predictive value of ΔSULmaxD15 of the primary breast cancer at a threshold of 40% and the ability of the niFDG-PET/CT biomarker to predict 3-year event free survival (EFS). Sample Size: We expect that 50% of patients will not reach the ΔSULmax threshold of 40% and a pCR rate of 40-60%. The proposed sample size is 210 participants, adjusted to 235 to account for missing data in 10% of cases. Computation of exact, two-sided 95% confidence intervals (CI) for NPV determined the lower limit of the CI is at least 80% when the true NPV is at least 88%. The lower limit is 84% when the true NPV has the value of 91%, which was estimated in the TBCRC026 study. Current Status: EA1211/DIRECT was activated in May 2023 across the NCI National Clinical Trials Network (NCTN), and accrual is anticipated to complete in March 2025. Those interested in the clinical trial can email ea1211team@ecog-acrin.org. Conclusion: The EA1211/DIRECT trial is the first step in implementing a Response-Guided Treatment Strategy by validating the ΔSULmax threshold of 40% as the optimum cut point across standard of care HER2-directed neoadjuvant regimens. If EA1211/DIRECT meets its objectives, the results will be used to design clinical utility studies, and thus hoping to change practice. Citation Format: Heather Jacene, Constantine Gatsonis, Roisin Connolly, Brian Burnette, Erica Stringer-Reasor, Maeve Hennessy, Justin Romanoff, Alexander Taurone, Ciara O'Sullivan, H. T. Carisa Le-Petross, Courtney Lawhn Heath, Vered Stearns, Amy Fowler, Shou-Ching Tang, Karla A Sepulveda, Angela DeMichele, David Mankoff, Antonio Wolff. ECOG-ACRIN EA1211: Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT Trial) [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-01-01.
Predicting Disease Relapse in ANCA Associated Vasculitis With Radiomics
Falde, S., Rajagopalan, S., Cartin‐Ceba, Rodrigo , Peikert, Tobias, Specks, Ulrich , Bartholmai, Brian J. , Rajagopalan, S.

Mayo Clinic

B80-1. METHODOLOGICAL ADVANCEMENTS IN PULMONARY IMAGING | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A4502-A4502

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a4502 Get It

Tracheobronchomalacia on Dynamic Expiratory View: Concordance Assessment in Interpretation
Matatko, M., Edell, Eric S. , Lim, Kaiser G. , Bartholmai, Brian J.

Mayo Clinic

B21. RESEARCH STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A3077-A3077

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3077 Get It

Bronchoscopic Lung Volume Reduction: Machine Learning Mathematical Model for Target Lobe Selection
Hostetter, Logan , Brown, L. E. , Rajagopalan, S., Scrodin, M. Dulohery, Edell, E.S., Lester, Michael , Maldonado, Fabien , Lentz, Robert J. , Peikert, T., Brown, L., Rajagopalan, S., Edell, Eric S. , Bartholmai, Brian J. , Peikert, Tobias

Mayo Clinic

B21. RESEARCH STUDIES IN INTERVENTIONAL PULMONARY AND PLEURAL DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A3065-A3065

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3065 Get It